Name | 5-cyclopropyl-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-amine |
---|---|
Synonyms |
5-Cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-pyrimidinamine
5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-amine 3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine bay-41-2272 4-pyrimidinamine, 5-cyclopropyl-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- unii-34a162j6wb BAY 41-2272 |
Description | BAY 41-2272 is a soluble guanylate cyclases (sGC) activator.Target: guanylate cyclaseBAY 41-2272 is a recently introduced novel orally available agent that directly stimulates soluble guanylate cyclase (sGC) and sensitizes it to its physiological stimulator, nitric oxide. BAY 41-2272 is a promising new therapeutic agent that goes beyond current therapeutic agents. BAY 41-2272 acts as an arterial vasodilator, resulting in a reduction of MAP and pulmonary artery pressure and a decrease in SVR and renal vascular resistance. BAY 41-2272 reduces pulmonary capillary wedge pressure in the absence of a decrease in right atrial pressure. [2] |
---|---|
Related Catalog | |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Boiling Point | 496.1±45.0 °C at 760 mmHg |
Molecular Formula | C20H17FN6 |
Molecular Weight | 360.388 |
Flash Point | 253.8±28.7 °C |
Exact Mass | 360.149872 |
PSA | 83.24000 |
LogP | 1.99 |
Vapour Pressure | 0.0±1.3 mmHg at 25°C |
Index of Refraction | 1.767 |
Storage condition | -20℃ |
Precursor 9 | |
---|---|
DownStream 0 |